A Scheduled Protocol for the Treatment of Juvenile Recurrent Respiratory Papillomatosis With Intralesional Cidofovir

Dinesh K. Chhetri, MD; Nina L. Shapiro, MD

Objective: To assess the efficacy of treating juvenile recurrent respiratory papillomas with intralesional cidofovir using a scheduled treatment protocol.

Design: Prospective case series.

Setting: Tertiary care academic medical center.

Patients: Of 5 pediatric patients with recurrent respiratory papillomas, 2 had severe recurrent papillomatosis requiring long-term therapy of laser ablations every 2 weeks prior to cidofovir treatments. The 3 other patients were newly diagnosed or had milder disease.

Intervention: Intralesional cidofovir (1 mg/kg) was administered during each scheduled visit. The first 4 treatments were at 2-week intervals (week 0, 2, 4, and 6). Subsequent treatment intervals were each increased by 1 week (treatments took place at week 9, 13, 18, 24, etc). Concomitant laser ablation was used only for bulky lesions.

Main Outcome Measures: Papilloma stage and need for laser ablation at each scheduled visit.

Results: The mean follow-up time was 66 weeks. The mean (SD) papilloma stage decreased from 9.2 (5.5) at initial presentation to 3.4 (2.6) within 2 weeks of the first injection (P<.05), and continued to decrease for the remaining of the follow-up period. Papilloma stage 0 was achieved in 4 of the 5 patients. The need for laser ablation of papillomas also decreased within 4 weeks of treatment initiation (P<.05). At 9 weeks, no patient required laser therapy. One patient was removed from the protocol after 58 weeks.

Conclusion: An intralesional treatment protocol with cidofovir and increasing intervals between scheduled treatment was successful the long-term management of juvenile respiratory papillomatosis.


Respiratory papillomatosis is the most common neoplasm of the larynx in children. Although benign, it has a potential for significant morbidity and mortality. Involvement of the larynx and the vocal cords leads to hoarseness and, if left untreated, can result in death from airway obstruction. Microsuspension direct laryngoscopy and carbon dioxide laser ablation of papillomatous lesions is the current standard treatment for this disease. The disease is characterized by its recurrent nature and is therefore more commonly referred to as recurrent respiratory papillomatosis (RRP). In some children with aggressive RRP, treatment is required as frequently as every 2 weeks for an extended time. Laser ablation requires general anesthesia and complications of laser therapy include permanent injury to the lamina propria of the vocal fold, leading to vocal fold scarring, laser-induced fire, and development of glottic webs. These considerations have driven the search for novel therapeutic modalities for the treatment of RRP.

The antiviral drug cidofovir (Gilead Sciences, Foster City, Calif) has recently been introduced into the armamentarium for treatment of RRP in several tertiary care centers. Cidofovir is a cytosine nucleotide analogue that was approved for treatment of cytomegalovirus retinitis in patients infected with human immunodeficiency virus. After entry into a cell the drug undergoes phosphorylation and its active metabolite, cidofovir diphosphate, selectively inhibits cytomegalovirus DNA polymerases. Incorporation of cidofovir into the growing DNA chain results in selective inhibition of viral DNA synthesis. The long intracellular half-life of cidofovir and its metabolites allows for infrequent dosing. Cidofovir has also been shown to be effec-
adults with RRP treated with intralesional cidofovir.7

 injections was the increase in intervals between operative
at mild levels in 9 of 10 patients.6 For the patient, the great-
crease in operative intervals. Complete response was
reduction of papillomas, airway improvement, and an in-
ponents, many questions remain unanswered. The optimal
dose, the frequency and duration of treatment, and the
proper candidates for intralesional cidofovir treatment have
not been determined. In addition, the toxic long-term effect
of this form of therapy is unknown. The major toxic ef-
fects of intravenous cidofovir include renal failure and neu-
ropenia. In addition, a concern for the potential devel-
opment of carcinoma has been raised, although no definite
case of laryngeal carcinoma as a result of intralesional
administration of cidofovir for RRP has been reported.

We developed a scheduled protocol for intralesional
cidofovir treatment of RRP. The protocol starts with short
treatment intervals, and the intervals are incrementally
lengthened. Laser ablation is performed concomitantly as
needed. The goal was complete eradication of disease or
control of disease to a point where laser ablations would
not be necessary. We first offered this treatment to a child

tive against a broad range of DNA viruses, including human
papillomavirus (HPV).2,8 Therefore, this drug has found
an off-label use in the treatment of RRP.2-7

Pransky et al5 first reported the successful use of ci-
dofovir for juvenile RRP. They treated 5 children who had
aggressive RRP with intralesional injections of cidofovir
in conjunction with laser ablation and noted a dramatic
reduction of papillomas, airway improvement, and an in-
crease in operative intervals. Complete response was
achieved in 3 patients. In an update with 5 more children
treated in a similar fashion, they reported continued im-
provement of the airway and maintenance of the disease
at mild levels in 9 of 10 patients.6 For the patient, the greatest
benefit from concomitant intralateral cidofovir injec-
tions was the increase in intervals between operative
interventions. We found similar results in a case series of
adults with RRP treated with intralateral cidofovir.7

While the clinical efficacy of intralateral cidofovir
therapy for RRP has clearly been suggested by multiple re-
ports, many questions remain unanswered. The optimal
dose, the frequency and duration of treatment, and the
proper candidates for intralateral cidofovir treatment have
not been determined. In addition, the toxic long-term effect
of this form of therapy is unknown. The major toxic ef-
fects of intravenous cidofovir include renal failure and neu-
ropenia. In addition, a concern for the potential devel-
opment of carcinoma has been raised, although no definite
case of laryngeal carcinoma as a result of intralateral
administration of cidofovir for RRP has been reported.

A scheduled treatment protocol was devised. The first 4 treat-
ments were scheduled every 2 weeks (week 0, 2, 4, and 6). Each
subsequent treatment took place at intervals increased by 1 week
(at week 9, 13, 18, 24, etc). Informed consent was obtained from a
parent or guardian at each treatment. The experimental na-
ture of the drug, its indication and injection method, and the
possibility of renal failure and neutropenia were specifically dis-
cussed. Blood was drawn prior to each injection and serum urea
nitrogen and creatinine values measured by the clinical labo-
atory. If these renal parameters were within normal limits and
not significantly changed from previous values, we proceeded
with cidofovir therapy. A complete blood cell count was not
routinely performed.

Microsuspension direct laryngoscopy and bronchoscopy were
carried out under spontaneous ventilation general anes-
thetia to assess for papillomas. A 0° 4.0-mm endoscope at-
tached to a video camera (Model 7210AA; Karl Storz, Culver
City, Calif) was used for photodocumentation of the larynx.
Four views of the upper airway were obtained: supraglottic, glot-
tic, subglottic, and tracheal. Treatment of papillomas pro-
ceded after photographs were obtained. If papillomatous le-
sions were absent or flat, a cidofovir injection alone was given.
Raised or bulky lesions were first removed with cup forceps,
then by laser ablation of the base, prior to cidofovir injection.

Cidofovir was diluted to a concentration of 5 mg/mL in an
isotonic sodium chloride solution and administered using a 22-
gauge 51⁄2-inch spinal needle on a 5-mL syringe. The interaryte-
radioscopy was performed prior to releasing the laryngeal suspen-
sion.

The papilloma staging system described by Derkay et al9
was used to score the anatomic severity of RRP at each treat-
ment (Figure 1). This staging system divides the larynx and
upper aerodigestive tract into anatomic subsites and assigns a
score to papillomatous lesions in those areas based on whether
papillomas are absent (score 0), flat (score 1), raised (score 2),
or bulky (score 3). All subsite scores are added and a cumulative
score is obtained for each patient at each treatment. The
photodocumentation obtained at each treatment was used to
score papillomas. The operative reports were also used for guid-
ance. The main outcome measures were papilloma stage and
use or nonuse of laser at each treatment. The level of signifi-
cance was kept at P<.05. The t test and the Fisher exact test
were respectively used to compare papilloma score and use of
laser at each treatment.

RESULTS

Five children, 3 boys and 2 girls between the ages of 22
months and 11 years at initial presentation, received in-
tralateral treatment with cidofovir. In all patients, ini-
tial papilloma biopsy samples were positive for HPV 6/11

Figure 1. Staging assessment for recurrent laryngeal papillomatosis.9

<table>
<thead>
<tr>
<th>Larynx</th>
<th>Epiglottis:</th>
<th>Lingual surface</th>
<th>Aryepiglottic folds:</th>
<th>Right</th>
<th>Left</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Arytenoids:</td>
<td></td>
<td>False vocal folds:</td>
<td>Right</td>
<td>Left</td>
</tr>
<tr>
<td></td>
<td>True vocal folds:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anterior commissure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Posterior commissure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Subglottis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trachea</td>
<td>Upper one third</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Middle one third</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lower one third</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Branch:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Epiglottis:</td>
<td>Lingual surface</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arytenoids:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>False vocal folds:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>True vocal folds:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anterior commissure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Posterior commissure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Subglottis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>Nose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Palate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharynx</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Esophagus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lungs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Score All Sites:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
0 = none, 1 = surface lesion, 2 = raised lesion, 3 = bulky lesion

©2003 American Medical Association. All rights reserved.

Downloaded From: https://archotol.jamanetwork.com/ by a Non-Human Traffic (NHT) User on 04/03/2019
but negative for HPV 16/18 and HPV 31/33/35. The average papilloma score, which was 9.2 at the first treatment, had decreased to 3.4 by the second treatment ($P = .01$) and continued to decrease thereafter (Table 1). Laser use was halted after 1 treatment in 1 patient, 2 treatments in 2 patients, and 4 treatments in 1 patient. One patient (patient 2) was not treated with laser therapy in this study because her larynx was scarred from previous laser therapies. The number of treatments with cidofovir ranged between 8 and 22, and the average follow-up time was 66 weeks (range, 31-123 weeks). Renal function was stable throughout the treatment period for all children (Table 2).

Four of the 5 children achieved complete resolution of papillomas (severity score, 0) during the course of their treatment. At the latest follow-up visit, 2 had no disease but 3 had mild residual disease (Table 1). The clinical course is described in detail for the first patient and a brief summary is provided for the remaining patients.

A 4-year-old boy (patient 1) presented with respiratory distress and a large pedunculated papillomatous lesion. After the obstructing lesion was removed urgently in the operating room, diffuse involvement of the larynx was seen (score 10). The disease was managed with repeated laser ablations. Despite 13 laser ablations in the following 34 weeks, his papilloma score remained between 10 and 20 (Figure 2). Intralesional cidofovir therapy was offered to him because of the severity of his papillomatosis. At the first scheduled treatment papillomas involved the true and false vocal cords bilaterally, plus the anterior commissure, left arytenoid, left posterior subglottis, and laryngeal surface of the epiglottis (score 14). The response to combined cidofovir and laser treatment was dramatic and in stark contrast to the previous course of the disease. By the third scheduled treatment the papilloma score was 3 and concomitant laser therapy was not needed. During the course of the scheduled treatments the child continued to have minimal residual papillomatosis but laser ablation was not performed until the scheduled week 48 treatment; then, it was used to remove a raised lesion at the right true vocal fold. Because

### Table 1. Papilloma Score and Laser Use at Each Scheduled Treatment Visit

<table>
<thead>
<tr>
<th>Treatment Week</th>
<th>Patient No., Score (Laser Use)</th>
<th>Average Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>14 (Yes) 7 (Yes) 6 (Yes) 16 (Yes) 3 (Yes)</td>
<td>9.2</td>
</tr>
<tr>
<td>2</td>
<td>3 (Yes) 2 (Yes) 8 (Yes) 3 (Yes)</td>
<td>3.4</td>
</tr>
<tr>
<td>4</td>
<td>3 (Yes) 0 (Yes) 6 (Yes) 1 (Yes)</td>
<td>3.0</td>
</tr>
<tr>
<td>6</td>
<td>3 (Yes) 0 (Yes) 3 (Yes) 1 (Yes)</td>
<td>1.8</td>
</tr>
<tr>
<td>8</td>
<td>3 (Yes) 0 (Yes) 1 (Yes) 0 (Yes)</td>
<td>0.8</td>
</tr>
<tr>
<td>10</td>
<td>2 (Yes) 0 (Yes) 5 (Yes) 0 (Yes)</td>
<td>1.4</td>
</tr>
<tr>
<td>12</td>
<td>2 (Yes) 0 (Yes) 3 (Yes) 0 (Yes)</td>
<td>1.0</td>
</tr>
<tr>
<td>14</td>
<td>4 (Yes) 0 (Yes) 2 (Yes) 0 (Yes)</td>
<td>2.0</td>
</tr>
<tr>
<td>16</td>
<td>3 (Yes) 0 (Yes) 3 (Yes) 0 (Yes)</td>
<td>1.2</td>
</tr>
<tr>
<td>18</td>
<td>5 (Yes) 1 (Yes) 2 (Yes) 1 (Yes)</td>
<td>2.0</td>
</tr>
<tr>
<td>20</td>
<td>2 (Yes) 0 (Yes) 3 (Yes) 0 (Yes)</td>
<td>1.7</td>
</tr>
<tr>
<td>22</td>
<td>1 (Yes) 0 (Yes) 2 (Yes) 1 (Yes)</td>
<td>1.0</td>
</tr>
</tbody>
</table>

*Weeks in parentheses are additional treatment weeks.

†Treatments were not given at these weeks because patients 3 and 5 were unavailable.

### Table 2. Renal Parameters at the Start and End of Study of Intralesional Treatment With Cidofovir (1 mg/kg) for RRP

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Treatment Weeks, No.</th>
<th>Injections, No.</th>
<th>SUN, mg/dL (mmol/L)</th>
<th>Creatinine, mg/dL (µmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Start</td>
<td>End</td>
</tr>
<tr>
<td>5</td>
<td>31</td>
<td>8</td>
<td>11 (4)</td>
<td>10 (4)</td>
</tr>
<tr>
<td>4</td>
<td>48</td>
<td>11</td>
<td>9 (3)</td>
<td>8 (3)</td>
</tr>
<tr>
<td>3</td>
<td>58</td>
<td>9</td>
<td>5 (2)</td>
<td>5 (2)</td>
</tr>
<tr>
<td>2</td>
<td>69</td>
<td>13</td>
<td>8 (3)</td>
<td>10 (4)</td>
</tr>
<tr>
<td>1</td>
<td>123</td>
<td>22</td>
<td>9 (3)</td>
<td>9 (3)</td>
</tr>
</tbody>
</table>

Abbreviations: SUN, serum urea nitrogen; RRP, recurrent respiratory papillomas.
he continued to have persistent residual papillomas, and the intervals between treatments were becoming long, he was taken off the scheduled protocol at 58 weeks and placed on a 5- to 8-week treatment schedule to avoid disease resurgence. After receiving combined laser and cidofovir treatments at weeks 69, 74, 81, and 86, his larynx was found clear of papillomas for the first time at week 94. At his latest scheduled treatment, at 48 weeks, he continued to have flat lesions at those sites (score 3). And patient 5, a 5-year-old girl, presented with a 4-month history of hoarseness and cough. Examination in the operating room revealed a large bulky papilloma emanating from the right false vocal cord (score 3) and obliterating the airway when collapsed. The lesion was urgently removed with cup forceps and the base ablated with the laser. Cidofovir treatment was then given. Her larynx remained clear of papillomas at her latest scheduled treatment, at 31 weeks (score 0).

**COMMENT**

Previous clinical reports on the efficacy of intralesional injections of cidofovir for papillomatosis indicated recurrence of disease when treatment was stopped, and even the possibility of disease recurrence with continued treatment. The treatment dose in those studies was approximately 1 mg/kg of cidofovir and the treatment interval was 2 to 3 weeks. While better control of RRP with the addition of cidofovir was demonstrated, how long the duration of treatment and how frequent the individual treatments should be remained unclear. Given the potential toxic effects of cidofovir, it is important for clinicians to have further guidelines on the use of this drug. Therefore, we designed the scheduled protocol for treatment of RRP with increasing treatment intervals. The dose was kept at 1 mg/kg but after 4 treatments at 2-week intervals, each subsequent treatment interval was increased by 1 week. An ideal result under this protocol is a well-managed and well-controlled disease, without need for unscheduled treatments or laser use. The patient would be managed indefinitely under this protocol, until the treatment intervals became so infrequent that a decision to terminate treatment could be made.

Our results demonstrate that intralesional treatments with cidofovir, combined with laser ablations as needed for bulky lesions, control juvenile RRP at levels of mild severity. Two of our patients (1 and 4) had se-
vere, poorly controlled RRP despite laser ablations almost every 2 weeks. Their disease became controlled only after addition of intralesional cidofovir treatments. One patient (1) was removed from the scheduled protocol after 58 weeks and the other (4) continues on the scheduled protocol with excellent control of his papillomas. The other 3 patients have had excellent responses, with no need for laser ablations except at the onset of treatment. At the latest follow-up, 2 of them had no evidence of papillomas and the third one has recently developed mild recurrence after a prolonged disease-free period. The last 3 patients had excellent response, but milder disease at the initiation of cidofovir therapy.

The better control of laryngeal papillomas achieved with the addition of intralesional injections of cidofovir to laser treatment resulted in decreased patient morbidity. We encountered no need for intubations before or after treatment, and there were no postoperative admissions, no readmissions, no unscheduled visits, and no administration of steroids. All 5 patients have a normal voice and all participate fully in their daily activities. Regarding the lesions of the 3 patients with persistent or recurrent disease, they are located at the anterior commissure and the posterior true vocal cords in 2 (1 and 4), in close proximity to the arytenoid cartilage. In the third patient (3), lesions are present at the posterior false vocal cords adjacent to the arytenoids. Persistence of disease in these locations may be related to inadequate drug delivery. We limit the amount of volume injected into the vocal folds to prevent overdistention of the lamina propria. In addition, the mucosal layer in the region of the anterior wall of the arytenoids and the anterior commissure abuts cartilage and is very thin, which limits the volume of medication that can be injected in these areas. Finally, we limit laser use to the anterior commissure and, therefore, rely solely on cidofovir to eradicate disease from this area. In our case series of adult patients, we also noted the persistence of papillomas at the anterior commissure despite cidofovir therapy.7

The role of cidofovir in the treatment of RRP remains to be fully established. We currently use it as adjuvant therapy to laser treatment for severe papillomatosis. Prospective randomized dose determination studies are needed to assess the true efficacy of this modality of treatment.

CONCLUSIONS

A scheduled protocol for the treatment of juvenile RRP with cidofovir, with increasing intervals between treatments, is effective in controlling this disease. Children with milder disease appear to respond better to this therapy. Further prospective studies are needed to establish the role of cidofovir in the treatment of RRP.

Submitted for publication March 21, 2002; accepted January 24, 2003.

This study was presented at the annual meeting of the American Society of Pediatric Otolaryngology (ASPO); May 13, 2002; Boca Raton, Fla.

Corresponding author: Dinesh K. Chhetri, MD, 62-132 CHS, Head and Neck Surgery, Mail Code 162418, UCLA School of Medicine, Los Angeles, CA 90095 (e-mail: dcchhetri@ucla.edu).

Reprints: Nina L. Shapiro, MD, 62-158A CHS, Head and Neck Surgery, Mail Code 162418, UCLA School of Medicine, Los Angeles, CA 90095.

REFERENCES